OncoSec 
Welcome,         Profile    Billing    Logout  
 2 Products   16 Diseases  2 Products   3 Trials   183 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tavo (tavokinogene telsaplasmid) / OncoSec
KEYNOTE 695, NCT03132675 / 2019-001409-26: Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment

Checkmark Data from KEYNOTE-695 study in combination with ImmunoPulse for melanoma at SITC 2020
Nov 2020 - Nov 2020: Data from KEYNOTE-695 study in combination with ImmunoPulse for melanoma at SITC 2020
Checkmark For KEYNOTE-695 study in combination with TAVO for stage III/IV melanoma
May 2020 - May 2020: For KEYNOTE-695 study in combination with TAVO for stage III/IV melanoma
Checkmark Data from PISCES trial in combination with TAVO at SITC 2019
More
Active, not recruiting
2
143
Europe, Canada, US, RoW
tavokinogene telseplasmid, pIL-12, tavo-EP, Pembrolizumab, Keytruda, ImmunoPulse
OncoSec Medical Incorporated, Merck Sharp & Dohme LLC
Stage III/IV Melanoma
03/23
07/24
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Active, not recruiting
2
17
US
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation
H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated
Melanoma
03/24
06/28
KEYNOTE-890, NCT03567720: Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Checkmark From KEYNOTE-890 trial in combination with TAVO for TNBC
Dec 2019 - Dec 2019: From KEYNOTE-890 trial in combination with TAVO for TNBC
Checkmark KEYNOTE-890 trial in combination with ImmunoPulse IL-12
Oct 2018 - Oct 2018: KEYNOTE-890 trial in combination with ImmunoPulse IL-12
Active, not recruiting
2
65
US, RoW
tavokinogene telseplasmid, pIL-12, tavo-EP, Pembrolizumab, Keytruda, Immunopulse, nab paclitaxel, Abraxane, gemcitabine plus carboplatin, Gemzar, Paraplatin
OncoSec Medical Incorporated, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
04/24
09/24
CORVax12 / OncoSec
No trials found
SPARK (TAVO+CXCL9) / OncoSec
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tavo (tavokinogene telsaplasmid) / OncoSec
KEYNOTE 695, NCT03132675 / 2019-001409-26: Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment

Checkmark Data from KEYNOTE-695 study in combination with ImmunoPulse for melanoma at SITC 2020
Nov 2020 - Nov 2020: Data from KEYNOTE-695 study in combination with ImmunoPulse for melanoma at SITC 2020
Checkmark For KEYNOTE-695 study in combination with TAVO for stage III/IV melanoma
May 2020 - May 2020: For KEYNOTE-695 study in combination with TAVO for stage III/IV melanoma
Checkmark Data from PISCES trial in combination with TAVO at SITC 2019
More
Active, not recruiting
2
143
Europe, Canada, US, RoW
tavokinogene telseplasmid, pIL-12, tavo-EP, Pembrolizumab, Keytruda, ImmunoPulse
OncoSec Medical Incorporated, Merck Sharp & Dohme LLC
Stage III/IV Melanoma
03/23
07/24
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Active, not recruiting
2
17
US
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation
H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated
Melanoma
03/24
06/28
KEYNOTE-890, NCT03567720: Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Checkmark From KEYNOTE-890 trial in combination with TAVO for TNBC
Dec 2019 - Dec 2019: From KEYNOTE-890 trial in combination with TAVO for TNBC
Checkmark KEYNOTE-890 trial in combination with ImmunoPulse IL-12
Oct 2018 - Oct 2018: KEYNOTE-890 trial in combination with ImmunoPulse IL-12
Active, not recruiting
2
65
US, RoW
tavokinogene telseplasmid, pIL-12, tavo-EP, Pembrolizumab, Keytruda, Immunopulse, nab paclitaxel, Abraxane, gemcitabine plus carboplatin, Gemzar, Paraplatin
OncoSec Medical Incorporated, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
04/24
09/24
CORVax12 / OncoSec
No trials found
SPARK (TAVO+CXCL9) / OncoSec
No trials found

Download Options